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Abstract

The aim of the study was to evaluate the human immunodeﬁciency virus (HIV) treatment cascade and mortality in migrants and
citizens living with HIV in Botswana.
Retrospective 2002 to 2016 cohort study using electronic medical records from a single center managing a high migrant case load.
Records for 768 migrants and 3274 citizens living with HIV were included. Maipelo Trust, a nongovernmental organization, funded
care for most migrants (70%); most citizens (85%) had personal health insurance. Seventy percent of migrants and 93% of citizens
had received antiretroviral therapy (ART). At study end, 44% and 27% of migrants and citizens, respectively were retained in care at
the clinic (P < .001). Among the 35% and 60% of migrants and citizens on ART respectively with viral load (VL) results in 2016, viral
suppression was lower among migrants (82%) than citizens (95%) (P < .001). Citizens on ART had a median 157-unit [95%
conﬁdence interval (CI) 122–192] greater increase in CD4+ T-cell count (last minus ﬁrst recorded count) than migrants after adjusting
for baseline count (P < .001). Five-year survival was 92% (95% CI = 87.6–94.8) for migrants and 96% (95% CI = 95.4–97.2) for
citizens. Migrants had higher mortality than citizens after entry into care (hazard ratio = 2.3, 95% CI = 1.34–3.89, P = .002) and ART
initiation (hazard ratio = 2.2, 95% CI = 1.24–3.78, P = .01).
Fewer migrants than citizens living with HIV in Botswana were on ART, accessed VL monitoring, achieved viral suppression, and
survived. The HIV treatment cascade appears suboptimal for migrants, undermining local 90-90-90 targets. These results highlight
the need to include migrants in mainstream-funded HIV treatment programs, as microepidemics can slow HIV epidemic control.
Abbreviations: AIDS = acquired immunodeﬁciency syndrome, ART = antiretroviral therapy, CI = conﬁdence interval, EMR =

electronic medical records, HIV = human immunodeﬁciency virus, HR = hazard ratio, IQR = interquartile range, LTFU = lost to followup, NGO = nongovernmental organization, OR = odds ratio, PLHIV = people living with HIV, PPP = public private partnership, USD =
United States dollar, VL = viral load.

Keywords: antiretroviral therapy, human immunodeﬁciency virus, migrants, mortality, treatment cascade, viral suppression
Editor: Barry Margulies.

1. Introduction

A poster abstract was presented at the International acquired immunodeﬁciency
syndrome Society (IAS) Conference, Amsterdam, Netherlands, July 2018.
Abstract number: WEPEB141.

To reach human immunodeﬁciency virus (HIV) epidemic control,
Joint United Nation Program on HIV and AIDS proposed the 9090-90 and the Fast-Track’s 95-95-95 targets, now pillars of the
world’s approach to HIV treatment.[1,2] The strategy seeks to
control HIV using testing to identify and treat all people living
with HIV (PLHIV), and achieve zero discrimination. The ultimate
goal is HIV incidence reduction. These targets cannot be achieved
without addressing microepidemics among subpopulations at
increased risk of HIV and providing equitable access to care.[3]
Despite progress globally and in sub-Saharan Africa toward the
90-90-90 targets,[4] some populations remain highly vulnerable,
including mobile populations, and are often excluded from
mainstream HIV treatment programs and experience speciﬁc
barriers to healthcare.
In sub-Saharan Africa, international migration generally
occurs from poorer to more economically and politically stable
nations. Mobile populations that move within a country (internal
migration) or cross borders (international migration) are a
priority in the HIV response.[5,6] Although the extent of the
association between migration and HIV transmission is debated,
population mobility hinders HIV prevention and treatment,[7]
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month, or partially fund (5% co-payment if earning USD200400/month. Higher-earning migrant families self-paid for ART
entirely, as did those with personal health insurance. All migrant
patients received free consultations from volunteer clinicians. A
standard ﬁrst-line ART regimen with zidovudine-lamivudineefavirenz costs approximately USD20/month, whereas tenofoviremtricitabine-efavirenz costs approximately USD25/month. HIV
RNA viral load (VL) test costs USD15.

with migrants living with HIV often struggling to access
treatment.[8,9]
Botswana is an upper middle-income country that attracts
refugees, asylum seekers, and immigrants (migrants or noncitizens), including those from countries with high HIV
prevalence, such as Zimbabwe, Zambia, and South Africa.[10]
In 2015, an estimated 161,000 documented migrants in
Botswana represented ∼7% of the total population.[11] With
many unskilled and undocumented migrant workers entering
Botswana, this ﬁgure undoubtedly underestimates the migrant
population. The inﬂux of migrant labor into Botswana may
hamper HIV prevention and control strategies at the end stages of
the epidemic.
Although economically and politically stable, Botswana has
the third-highest adult HIV prevalence globally—18.5%.[12] The
country’s HIV response is commendable; an estimated 87.4% of
citizens diagnosed and living with HIV receive antiretroviral
therapy (ART) and an estimated 96.5% are virologically
suppressed.[13] However, while citizens have free ART access,
migrants must obtain Botswana citizenship, marry a citizen, be
born to a citizen, or be documented refugees conﬁned to a camp
to qualify. Many international migrants in Botswana do not
qualify and cannot afford medical care and HIV treatment. Cost,
negative attitudes of medical staff, fear of police/immigration
ofﬁcers, and language are additional barriers to migrant
healthcare.[14]
Maipelo Trust, a nongovernmental organization (NGO)
funded primarily by the US-based NGO Cover the Globe,
subsidizes or fully funds services such as HIV diagnostics and
ART for ﬁnancially constrained migrants in Botswana. The
funding supports the Independence Surgery, a private clinic in
Gaborone, that since 2002 has provided HIV care to migrants
from Zimbabwe, Zambia, Kenya, Mozambique, and other
countries, and to Botswana citizens funded through a publicprivate partnership (PPP).
We report the outcomes of independence surgery patients,
comparing retention of migrants and citizens in the latter stages
of the HIV treatment cascade (ART coverage, viral suppression,
and retention in care at the clinic), and mortality after entry into
care and after ART initiation.

2.2. Study participants
All PLHIV accessing the clinic between January 2002 and
December 2016 were included. Children were deﬁned as anyone
younger than 18 years.[15] Some patients were on ART when
referred to the clinic. PLHIV were categorized as migrants
(individuals born outside the country, without Botswana
citizenship) or citizens (individuals with a national identity card).
2.3. Deﬁnitions of variables
World Health Organization immunological staging was used to
determine CD4+ T-cell categories based on the following CD4+
counts; severe: <200 cells/mL; advanced: 200 to 349 cells/mL;
mild: 350 to 499 cells/mL; and none/not signiﬁcant: ≥500 cells/
mL.[16] ART coverage included all patients ever on ART, before
ﬁrst clinic visit or initiated at the clinic. The viral suppression
threshold was deﬁned as per national guidelines at VL <400
copies/mL.[17]
Retention in care at the Independence Surgery was deﬁned as
being in care (a documented clinic/pharmacy visit or laboratory
visit/test) during the study’s ﬁnal year (2016) irrespective of ART
status.[18] All patients lost to follow-up (LTFU), transferred, dead
or with incomplete records to verify retention were classiﬁed as
not retained in care. LTFU was based on a 90-day window of a
missed clinic/pharmacy reﬁll/laboratory visit for a patient initially
in care.
Funding pathways for migrants were NGO fully funded, NGO
partially funded, self-paying/personal health insurance, and
refugee.
2.4. Procedures/data sources

2. Design
We conducted a retrospective cohort study of all PLHIV
attending the Independence Surgery, Gaborone, Botswana
between 2002 and 2016. Electronic medical records (EMRs)
capturing socioeconomic, laboratory, and clinical data of PLHIV
were analyzed to determine funding pathway, ART status,
immunological status (CD4+ T-cell count), viral suppression,
retention in care at the clinic, and mortality.

A Microsoft Excel database was generated from the EMR system,
containing all records for individuals with an ART initiation date
(or on ART at ﬁrst clinic visit), ART regimen, and/or a follow up
VL in 2002 to 2016. ART regimens were based on a nonnucleoside reverse transcriptase inhibitor or protease inhibitor, or
integrase inhibitor with a nucleoside reverse transcriptase
inhibitor backbone. Viral suppression was assessed in the ﬁnal
study year for patients retained in care.

2.1. Setting

2.5. Statistical methods

Citizens’ HIV care was self-funded or through personal health
insurance or the PPP. The PPP scheme operated between
February 2006 and November 2013; thereafter, PPP patients
and other citizens used government clinics. Migrants at the
Independence Surgery self-paid, had personal health insurance,
or were partially/fully funded by the Maipelo Trust (which fully
or partially funded ART, but rarely laboratory costs). Migrant
families were ﬁnancially means tested; the Trust fully funded
ART for those earning less than United States dollar (USD) 200/

We used descriptive statistics to describe funding pathway, ART
coverage, viral suppression, and mortality for migrants and
citizens. Groups were compared using Pearson’s Chi-squared
test. Logistic regression was used to identify associations between
key variables (sex, age, duration of ART, ART regimen, CD4+
count, migrant/citizen) with viral suppression and retention in
care; CD4+ count categories (<200; 200–349; 350–499; >500
cells/mL) were used. Kaplan-Meier analysis with log-rank
statistics was used to compare time to ART initiation.
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All-cause mortality was evaluated by Kaplan-Meier functions
and Cox proportional hazards regression. Cohort entry was
determined as the date of ﬁrst clinic visit for PLHIV, and patients
were censored at transfer out of care, LTFU, or end of sampling
period (December 2016). To estimate the total effect of
citizenship status on all-cause survival, we performed an
unadjusted analysis. The total effect of citizenship on survival
was estimated using an adjusted analysis. We hypothesized that
the effects of citizenship on survival would be mediated by ART,
baseline degree of illness, age at care entry, and period effects; we
then performed a multivariable analysis adjusting for ART
initiation, baseline CD4+ count, age, and calendar year at care
entry to estimate residual direct effects. Effect measure
modiﬁcation was explored using graphical methods; no interaction effects were sufﬁciently inﬂuential to retain in the model. Due
to potential for survival bias between care entry and ART
initiation, we performed a complementary analysis on new
initiators of ART—left truncated at ART initiation—to evaluate
survival, unadjusted and adjusted for age, CD4+ count, and year
at clinic entry.
Baseline and follow-up CD4+ counts for ART patients were
compared using mean CD4+ counts and CD4+ count categories
between groups using chi-squared tests. Proportions of migrant
and citizen patients with severe immunosuppression (CD4+
count <200 cells/mL) were compared at baseline and follow-up.
Immunological response for patients on ART was analyzed using
quantile median regression; CD4+ counts were compared
between baseline and follow-up CD4+ count at study end. A
median regression was preferred over conventional mean
regression due to marked skew in the CD4+ count data which
was further resistant to common transformations (i.e., the count
data remained skewed after log and square-root transformation).
Factors associated with immunological response levels were
analyzed in a univariate logistic regression model containing
gender, age, duration of ART, ART regimen, CD4+ count, and
migration status.
Statistical signiﬁcance was deﬁned as a 2-sided P value <.05.
Analysis was performed using Stata version 14 statistical
software (College Station, TX).

Table 1
Demographic characteristics of migrants and citizens.
Variable
Age
Median age (range), y
No. children (<18 y)
Sex
Male
Female
Funding pathway
NGO funded
Partially funded (% of NGO funded)
Fully funded (% of NGO funded)
Refugees (ofﬁcial)
Self-paying/health insurance
Government PPP scheme
Country of origin
Botswana
Zimbabwe
Zambia
Kenya
Malawi
Other (Malawi, South Africa,
Tanzania, Mozambique)
Unknown

Migrants
(N = 768) n (%)

Citizens
(N = 3274) n (%)

39 (0.25–84)
139 (18)

48 (0.25–92)
34 (1)

335 (44)
432 (56)

1283 (39)
1991 (61)

534 (70)
281 (52)
253 (48)
8 (1)
226 (29)
N/A

N/A
N/A
N/A
N/A
2773 (85)
501 (15)

∗

21 (3)
606 (79)
28 (4)
10 (1)
10 (1)
20 (3)

3274 (100)
N/A
N/A
N/A
N/A
N/A

62 (8)

N/A

NGO = nongovernmental Organization, PPP = public-private partnership.
∗
Included children born by migrant and citizen parents, and married to citizens with no legal
documents to access free healthcare services.

3.1. ART coverage
Ninety percent (n = 3642) of all PLHIV received ART during the
study; 77% (n = 593) of migrants and 65% (n = 2385) initiated
ART at the clinic. Migrants initiated ART more rapidly than
citizens; median times to ART initiation from ﬁrst clinic visit were
11 days [interquartile range (IQR): 1–142 days] and 91 days
(IQR: 7–748), respectively (P < .001). Seventy-six percent of
migrants and 58% of citizens initiated ART within 6 months of
ﬁrst clinic visit (P < .001).
ART coverage was higher among NGO fully funded migrants
(77%; n = 195) than refugees (60%; n = 3), NGO partially funded
migrants (46%; n = 246), and self-paying/personal health insurance migrants (29%; n = 226). Citizens on the PPP scheme were
more likely to be on ART (99%; n = 498) than self-paying/
personal health insurance citizens (85%; n = 2773). Self-paying/
personal health insurance migrants were less likely to be on ART
than self-paying/personal health insurance citizens (P < .001)
(Table 2).

2.6. Ethical considerations
The Botswana Ministry of Health Human Research Review
Committee, Children’s Mercy Institutional Review Board,
Monash University, and University of Washington approved
the study. Consent was waived because the study involved a
retrospective chart review with deidentiﬁed data. The study was
classiﬁed as posing minimal risk to study participants.

3. Results
3.2. Retention in care at the Independence Surgery

Of the 4042 PLHIV registered at the clinic in 2002 to 2016, 20%
(n = 768) were migrants and 80% (n = 3274) citizens (Table 1). At
ﬁrst clinic visit, migrants were younger and included more
children than citizens (18% vs 1%). Most patients were female
(56% and 61% among migrants and citizens, respectively).
Migrants’ care was funded by the NGO (70%) (partially/fully
funded) or self-paid/personal health insurance (29%). Most
migrants receiving HIV care at the clinic were from Zimbabwe
(79%). Most citizens had HIV care funded through personal
health insurance (85%) or the PPP scheme (15%) (Table 1).

Of 768 migrants, 44% (n = 341) were retained in care at the
Independence Surgery in the last study year; 48% (n = 372) had
incomplete records to ascertain retention, 2% (n = 18) had
transferred, and 5% (n = 37) died. Of the 3274 citizens, 27% (n =
891) were retained in care, 70% (n = 2261) transferred to
government clinics, and 4% (n = 122) died. The overall median
time retained in care was 4.3 years (IQR: 0.2–9.8 years); 1.2 years
(IQR: 0.1–4.2 years) for migrants, and 5.9 years (IQR: 1.2–10.3)
for citizens.
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Self-paying/personal health insurance migrants (50/226) were
less likely to be retained in care than self-paying citizens (891/
2773) (22% vs 32%; P = .002). Fifty-eight percent (n = 146) of
NGO fully funded migrants, 49% (n = 139) of partially funded
migrants and 6 of 8 (75%) refugees were retained in care.
Due to a high proportion of citizens being transferred to
government clinics in November 2013, a higher proportion of
migrants were classiﬁed as retained in care at the Independence
Surgery (44%; n = 341) than citizens (27%, n = 891) [unadjusted
odds ratio (OR) = 0.54; P < .001]. Overall, female sex (unadjusted OR 1.25; P < .002), Zimbabwe nationality (OR 1.99;
P < .001), and baseline CD4+ count category 350 to 499
(unadjusted OR 1.26; P = .04 vs CD4+ count <200 cells/mL)
were associated with retention in care at the Independence Clinic.

Table 2
Clinical outcomes of migrants and citizens on antiretroviral
therapy.
Migrants
(N = 768)
n (%)

Variable
ART coverage
ART coverage, overall
Sex
Males
Females
Age
Children
Adults
Funding pathway
NGO partially funded
NGO fully funded
Self-paying
PPP scheme
Refugees
ART regimen
NNRTI based
PI based
Integrase inhibitor
Unspeciﬁed
Other
Retained in care
Available VL results (on ART)
(% retained)
Viral suppression (% available
results)
CD4+ T-cell counts
Available CD4+ T-cell results
Baseline CD4+<200 cells/mL
Mean baseline CD4+ count

Citizens
(N = 3274)
n (%)

P

609 (79)

3033 (93)

<.001

260/335 (78)
349/432 (81)

1191/1283 (93)
1842/1991 (93)

.04
.04

81/139 (58)
528/629 (84)

26/34 (76)
.03
3007/3239 (93) <.001

246/281 (88)
195/253 (77)
165/226 (73)
N/A
3/5 (60)

N/A
N/A
2535/2773 (91) <.001
498/501 (99)
N/A

407 (53)
71 (9)
10 (1)
121 (16)
2 (<1)
341 (44)
119 (35)

1600 (49)
283 (9)
102 (3)
1048 (32)
2 (<1)
891 (27)
535 (60)

.04
.99
.002
<.001
.99
<.001
<.001

98 (82)

507 (95)

<.001

3024 (92)
1541 (51)
260 (SD 4.9;
CI: 250–269)
595 (19.7)
473 (462–484)

<.001
.14
.03

521 (68)
276 (53)
290 (SD 17.3; 95%
CI: 256–325)
Follow-up CD4+<200 cells/mL
191 (36.7)
Mean follow-up CD4+ count
456 (CI 295–616)

3.3. Viral suppression
Of 341 migrants retained in care, 35% (n = 119) had VL results
and 82% (n = 98) had viral suppression. Of the 891 citizens
retained in care, 60% (n = 535) had VL results and 95% (n = 507)
had viral suppression. Migrants had signiﬁcantly lower viral
suppression than citizens (P < .001) (Table 2).
Self-paying citizens had the highest viral suppression (95%;
507/534), followed by self-paying migrants (93%; 26/28) and
NGO fully funded migrants (84%; 31/37). The lowest level of
viral suppression was among partially funded migrants (75%;
38/51). All 3 refugees with VL results were virologically
suppressed.
In univariate analysis, citizenship (unadjusted OR 1.40;
P = .01), female sex (OR 1.39; P < .001), and baseline CD4+
count 200 to 249 cells/mL (compared to <200 cells/mL) (OR 1.35;
P = .01) were associated with greater odds of viral suppression.
Children had lower odds of viral suppression (OR = 0.49;
P = .02).
The HIV treatment cascade for migrants and citizens (Fig. 1)
shows ART coverage, viral suppression, and retention in care at
Independence Surgery. Overall, the HIV treatment cascade for
migrants was inferior to that of citizens.

<.001
.63

Viral suppression = HIV RNA VL <400 copies/m>; P value for chi-squared test.
ART = antiretroviral therapy, NGO = nongovernmental organization, NNRTI = non-nucleoside reverse
transcriptase inhibitor, PI = protease inhibitor, SD = standard deviation, VL = viral load.

Percent (%)

HIV Treatment Cascade for Migrants and Cizens
100
90
80
70
60
50
40
30
20
10
0

Migrants

Cizens

ART Coverage (%)

79

93

Viral suppression (%)*

82

95

Retained in care at clinic (%)

44

27

Later part of the HIV treatment cascade. VL: Viral load; *Viral suppression among those
with available VL results and on ART
Figure 1. Human immunodeﬁciency virus (HIV) treatment cascade for migrants and citizens. ART = antiretroviral therapy.
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Figure 2. Kaplan-Meier survival estimates for migrants (Maipelo) versus citizens (non-Maipelo).

3.4. Immunological response

National HIV prevalence in Botswana is estimated to be
>20%,[11,19] similar to a recent estimate of 20% among migrants
in peri-urban settings.[20] However, 2 previous migrant HIV
prevalence estimates were 1% and 29%.[21,22] Although the
prevalence of HIV in migrant populations in Botswana is
uncertain, high prevalence in neighboring source countries
suggests migrants should be considered in the local HIV response.
Importantly, social mixing occurs between migrants and
citizens,[23] so sexual networks of migrants and citizens are
probable. Hence, migrants can facilitate HIV spread if they are
unable to access or be maintained on treatment.
Botswana has achieved high HIV treatment coverage and viral
suppression rates among its citizens, meeting the 90-90-90
targets.[4,13] This study, however, suggests that treatment
coverage and viral suppression in migrants is lower than in
citizens; moreover, migrants experience later HIV testing and
diagnosis.[24,25] Although migrants can access free HIV testing in
Botswana, they cannot access free HIV treatment from a
government clinic. Other studies show lack of access to
healthcare services is often a barrier to HIV treatment among
migrant populations, who are typically socioeconomically
disadvantaged.[26] In our study, only 29% of migrants had
personal health insurance or could self-pay for HIV care and one
percent had accessed HIV care through a refugee camp. Given the
Maipelo Trust supports only a minority of migrants living with
HIV in Botswana, with many migrants unaware of the NGO’s
support, and others unable to afford visits and VL testing, many
migrants in Botswana lack access to HIV care and treatment.
Consequently, migrants will engage in care late, increasing time
to viral suppression, leading to poorer outcomes, and increased
transmission risk.[21] However, the results of our study suggest
migrants with access to care do relatively well, as evidenced by
shorter time to ART initiation in migrants than citizens. The hope
is to align migrant HIV care to the national program which
includes early/same day ART initiation and the use of
dolutegravir in ﬁrst-line regimen. In addition, treatment coverage
was high in individuals fully funded by the NGO, suggesting that
where there is equal access, positive outcomes are expected.

Sixty-eight percent of migrants and 92% of citizens had baseline
CD4+ count results; the proportions of migrants and citizens with
severe immunosuppression (CD4+ count <200 cells/mL) at
baseline were similar (Table 2). A quantile median regression
analysis showed citizens on ART had a median 157-unit (95% CI
122–192) greater increase in CD4+ count (last minus ﬁrst
recorded count) than migrants after adjusting for baseline count
(P < .001). Female sex was associated with a median 47-unit
(95% CI 19–75) greater increase in CD4+ count than male sex
(P < .001). A baseline CD4+ count category 200 to 349 cells/mL
was associated with a median 59-unit (95% CI 88–30) greater
decrease in CD4+ count than CD4+ count <200 cells/mL
(P < .001).
3.5. Mortality
Mortality was higher among migrants, with overall 5-year
survival of 92% (95% CI: 87.6–94.8) compared to 96% (95%
CI: 95.4–97.2) for citizens (P < .001) (Fig. 2). Crude hazard of
mortality was signiﬁcantly higher among migrants, and those
aged >35 years, those with a baseline CD4+ count <200 cells/mL,
and those not on ART (Table 3). The relationship between
migrant status and mortality was nonsigniﬁcant after adjustment
for these covariates. When restricted to those who initiated ART
at the clinic, crude survival was still lower in migrants, and in
people aged >35 years and with CD4+ count <200 cells/mL
(Table 3).

4. Discussion
Few researchers have compared HIV outcomes of migrants and
citizens in sub-Saharan Africa. We found that migrants in
Botswana had lower ART coverage, VL monitoring while on
ART, viral suppression rates, and higher mortality than citizens.
The study highlights how nationality and access to treatment
services inﬂuence outcomes amongst PLHIV in Botswana.
5
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Table 3
Cox models: overall and left-truncated mortality for migrants and citizens.
Overall

Left truncated analyses

Univariable
Mortality HR

P

Multivariable
95% CI

Mortality HR

P

95% CI

Lower Upper
Group
Migrants
Citizens
Patient age
<18 y
18–35 y
36+ y
Baseline CD4+
<200
200–349
350+
ART therapy
Quartile 1 (0–0.019 y)
Quartile 2 (0.02–0.199 y)
Quartile 3 (0.2–1.79 y)
Quartile 4 (1.8–20.6 y)
Did not initiate ART
First visit
1998–2007
2008–2016

Univariable
Mortality HR

Lower Upper

P

Multivariable
95% CI

Mortality HR

95% CI
P

Lower Upper

Lower Upper

2.291
-ref-

.002 1.349 3.892
—
—
—

1.413
-ref-

.27 0.764 2.611
— —
—

2.160
-ref-

.01 1.235 3.776
— —
—

1.954
-ref-

.06 0.970 3.939
— —
—

0.274
-ref1.854

.20 0.038 1.994
—
—
—
.003 1.226 2.803

0.288
-ref1.346

.22 0.039 2.140
— —
—
.17 0.883 2.052

0.357
-ref1.850

.31 0.049 2.604
— —
—
.01 1.198 2.858

0.464
-ref1.632

.45 0.063 3.425
— —
—
.03 1.050 2.536

3.502
1.283
-ref-

<.001 1.896 6.468
.53 0.585 2.812
—
—
—

2.937
1.222
-ref-

.001 1.538 5.609
.62 0.552 2.705
— —
—

3.259
1.259
-ref-

.001 1.672 6.351
.59 0.544 2.916
— —
—

2.795
1.167
-ref-

.003 1.422 5.494
.72 0.503 2.705
— —
—

-ref0.844
0.264
0.220
2.170

—
.52
<.001
<.001
.04

—
1.414
0.520
0.422
4.587

-ref0.859
0.329
0.328
3.454

—
.57
.002
.001
.002

—
—
—
.002 1.311 3.439

-ref1.340

— —
—
.31 0.759 2.364

-ref1.557

— —
—
.10 0.923 2.626

-ref1.063

— —
—
.86 0.549 2.058

-ref2.124

—
0.504
0.135
0.114
1.026

—
0.509
0.165
0.166
1.596

—
1.450
0.657
0.650
7.475

Left truncated analyses: restricted to new users if ART. It complements the total cohort because there is survival bias for who gets on ART. This analysis looks at survival after starting ART.
ART = antiretroviral therapy, CI = conﬁdence interval, HR = hazard ratio.

+ count, HIV-related death, drug resistance, and noncontinuity of
HIV care.[25] In our study, fewer migrants than citizens initiated
ART, possibly because of transport costs; these were (possibly)
undocumented migrants unable to move freely and/or whose
income-generating activity precluded medical appointments.
While our study did not capture migrants’ legal status,
undocumented migrants are more likely to be LTFU and
treatment access and success has also been shown to vary,
sometimes depending on migration status. Ridolfo et al[32] found
that the frequency of LTFU was higher in undocumented than
documented migrants, but they had similar viral suppression
rates. In our study, viral suppression was signiﬁcantly higher in
citizens (73%) than migrants (66%); a study in Kenya found
similar, unacceptably low viral suppression rates in refugees and
host nationals (74% and 70%; P = .66).[33]
Where policies promote equal access to ART and other
healthcare services, migrants may achieve similar outcomes to
citizens. Since 2007, South Africa has provided ART to refugee/
asylum seekers with or without documentation.[34] McCarthy
et al[35] demonstrated good treatment outcomes among foreigners/migrants receiving ART in South Africa; foreigners living with
HIV had faster median time to ART initiation (14 vs 21 days,
P = .008), as in our study (11 vs 101 days, P < .001). In our study,
migrants rapidly initiated ART because clinicians tried to
expedite treatment in some migrants who could not afford
baseline laboratory investigations. Citizens in our study
sometimes moved between private and government clinics. In
the South African study, migrants had fewer hospital admissions,
fewer missed appointments for ART initiation, better retention in
care, lower mortality, and were less likely to fail ART than
citizens. Ignoring undocumented status seems to promote
healthcare access for migrants, leading to better outcomes.[36]

At baseline, about half of migrants and citizens had severe
immunosuppression, but citizens had better immune response to
treatment. Our ﬁndings echo a European study showing migrants
had signiﬁcantly lower CD4+ counts and more acquired
immunodeﬁciency syndrome events at baseline.[27] This study
also showed that migrants were less likely to initiate ART, and
had higher virologic and treatment failure. Children had lower
odds of viral suppression compared to adults most-likely because
children had better access to VL testing. However, the concern is
whether children are being left behind with low viral suppression.[28,29] Where ART initiation and viral suppression rates are
low, due to socioeconomic factors, immunological response is
slow, as seen in migrants in Botswana. In other settings, late HIV
diagnosis remains a concern, especially in migrants.[30,31]
Overall survival in migrants was worse, but may be mitigated
by ART use. The greater mitigation of mortality risk in the overall
cohort than in those initiating ART during the study suggests that
ART initiation is a major driver of the observed mortality effect.
However, other factors, which treatment cannot address, such as
baseline illness (CD4+ count) and age, also affect survival. Our
result suggests that not all the effects of citizenship status on
survival are mediated by ART initiation, baseline degree of illness
(CD4+ count), age, or period effects (as a measure of healthcare
system changes over time). Migrants experienced higher
mortality, often related to baseline characteristics, and whilst
mortality may be partially mitigated by ART initiation, other
interventions may be necessary to reduce mortality, such as
earlier diagnosis and entry into care. Other factors related to
noncitizen status may also contribute to mortality but were not
measured here.
Healthcare systems often fail migrants; mobility is known to be
associated with ART nonadherence, LTFU, deterioration in CD4
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We did not collect data on nutritional status and other
opportunistic infections which may impact mortality.[37,38]
Tanser et al[25] found that migrants experience disparities in
healthcare access due to legal status, unfamiliarity with the host
environment, poor communication skills, and negative experience of culturally insensitive healthcare services and practices. As
outlined above, citizens and migrants mix in Botswana, although
the extent of their social and sexual networks is unknown and
there have been no phylogenetic studies conﬁrming HIV
transmission between these groups. However, given the nature
of how HIV transmits it is likely that not providing access to
testing and treatment for migrants will negatively impact on
Botswana’s efforts to reduce HIV incidence.
The main limitations of our study were incomplete records and
missing data. This hampered correctly classifying patients as
retained or not retained in care, as well as viral suppression. We
did not follow up patients who missed visits or those who
transferred out to determine mortality or other clinical outcomes.
Attempts to contact LTFU patients were hampered by inability to
conduct home visits and patients’ cross-border mobility. The
clinic also transitioned from a paper-based to EMR system during
the study, which may have affected data entry.

5. Conclusion
Migrants living with HIV have poorer clinical outcomes than
citizens, probably due to inability to pay for HIV care and
treatment services. Migrants described herein were less likely to
be on treatment or access VL monitoring, and had low viral
suppression and higher mortality than citizens. The HIV
treatment cascade was suboptimal for migrants and likely to
negatively impact on the 90-90-90 target achievement; this will
affect population-level HIV incidence reduction due to ongoing
viremia in this subpopulation. These results highlight the need
to include migrants in mainstream-funded HIV treatment
programs, as microepidemics can slow or reverse HIV
epidemic control.
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